Press Releases April 8, 2026 08:00 PM

BellRing Brands Announces Timing of Second Quarter Fiscal Year 2026 Earnings Release and Conference Call

BellRing Brands schedules Q2 fiscal 2026 earnings release and conference call for May 5, 2026

By Derek Hwang
Share
Twitter Reddit Facebook LinkedIn
BRBR

BellRing Brands, a leading consumer wellness and nutrition company, announced that it will release its second quarter fiscal 2026 financial results and provide its outlook for the full fiscal year on May 5, 2026. Following the release, an earnings conference call will be held to discuss the results and outlook. The company is recognized for its top brands Premier Protein and Dymatize, and operates across multiple retail channels globally.

BellRing Brands Announces Timing of Second Quarter Fiscal Year 2026 Earnings Release and Conference Call
BRBR
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Earnings release and fiscal year 2026 outlook scheduled for May 5, 2026.
  • Conference call with CEO and CFO to discuss results and future guidance.
  • BellRing Brands operates leading wellness and nutrition brands distributed worldwide across diverse retail channels.

ST. LOUIS, April 09, 2026 (GLOBE NEWSWIRE) -- BellRing Brands, Inc. (NYSE:BRBR) today announced it will release its financial results for the second quarter of fiscal year 2026 and its fiscal year 2026 outlook on May 5, 2026 at 7:00 a.m. ET. The release will be followed by a conference call at 8:30 a.m. ET to discuss the results and outlook. Darcy H. Davenport, President and Chief Executive Officer, and Paul A. Rode, Chief Financial Officer, will participate in the call.

Interested parties may join the conference call by registering in advance at the following link: BellRing Q2 2026 Earnings Conference Call. Upon registration, participants will receive a dial-in number and a unique passcode to access the conference call. Interested parties are invited to listen to the webcast of the conference call, which can be accessed by visiting the Investor Relations section of BellRing’s website at www.bellring.com. A webcast replay also will be available for a limited period on BellRing’s website in the Investor Relations section.

About BellRing Brands, Inc.

BellRing Brands, Inc. (NYSE: BRBR) is a dynamic and fast-growing consumer brands business with the purpose of Changing Lives with Good Energy. Focused on growing the proactive wellness category, the company’s brands include Premier Protein, the #1 ready-to-drink protein and proactive wellness brand, and Dymatize, the brand behind the #1 hydrolyzed protein powder. A culture-driven, pure-play company, BellRing Brands believes nutrition is at the core of a healthy world and produces products with best-in-class nutritional profiles and exceptional flavors. Its products are distributed in over 90 countries across club, mass, food, eCommerce, specialty, drug and convenience. To learn more visit www.bellring.com.

Contact:
Investor Relations
Jennifer Meyer
[email protected]
(415) 814-9388


Risks

  • Uncertainty regarding actual financial performance versus market expectations.
  • Potential volatility in consumer demand within the proactive wellness and nutrition sector.
  • Risks related to global distribution and multi-channel sales execution impacting revenue.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026